Oligonucleotide Synthesis Markets 4th Edition. Forecasts by Oligo Length, Application, Category, Type, Product, and Region. With Executive and Consultant Guides. 2026 to 2030. Includes Impact of Artificial Intelligence.

Description

Market Overview:

Synthetic oligonucleotide synthesis refers to the chemical or enzymatic production of short strands of DNA or RNA designed for use in research, diagnostics, and therapeutic applications. Oligonucleotides typically consist of sequences ranging from approximately 15 to 200 nucleotides, although longer constructs may be assembled through additional molecular biology techniques. These synthetic nucleic acid molecules play essential roles in modern genomics, molecular diagnostics, gene editing, and nucleic-acid-based therapeutics.

The global Synthetic Oligonucleotide Synthesis market has experienced strong growth as advances in molecular biology, genomic medicine, and biotechnology have expanded demand for custom DNA and RNA sequences. The market size in 2025 is USD 3.68 billion. The market is growing at 14.8%. The market will reach USD 7.35 billion in 2030.

Growth is being driven by expanding applications in polymerase chain reaction (PCR), next-generation sequencing (NGS), gene editing technologies such as CRISPR, antisense therapeutics, RNA interference (RNAi), messenger RNA (mRNA) technologies, and synthetic biology research. Increasing adoption of precision medicine approaches is also supporting demand for custom oligonucleotide synthesis services.

Role in Molecular Biology and Genomics

Synthetic oligonucleotides are fundamental tools in molecular biology workflows. PCR primers and probes rely on short DNA sequences designed to bind specific genetic regions, enabling amplification and detection of target sequences. Oligonucleotides are also used in sequencing library preparation workflows, hybridization assays, and gene expression analysis.

Advances in next-generation sequencing technologies have significantly increased demand for custom oligonucleotides used in sequencing adapters, indexing primers, and capture probes. High-throughput sequencing workflows often require large numbers of unique oligonucleotide sequences, supporting continued market expansion.

Gene editing technologies such as CRISPR-Cas systems also rely on synthetic oligonucleotides to create guide RNAs that direct genome modification activity. Increasing use of gene editing tools in research and therapeutic development is creating additional demand for high-quality synthetic nucleic acids.

Synthetic oligonucleotides also play a critical role in synthetic biology, where DNA sequences are designed to construct biological circuits or engineered microorganisms.

Therapeutic Applications

One of the fastest-growing segments of the synthetic oligonucleotide synthesis market is nucleic-acid-based therapeutics. Antisense oligonucleotides (ASOs), small interfering RNA (siRNA), microRNA-based therapies, and messenger RNA (mRNA) therapeutics represent important therapeutic modalities targeting gene expression pathways.

RNA-based therapeutics have attracted significant investment due to their ability to target disease mechanisms at the genetic level. Oligonucleotide therapies are being developed for rare genetic disorders, cancer, cardiovascular disease, and neurological conditions.

Chemical modifications such as phosphorothioate linkages, locked nucleic acids (LNAs), and peptide nucleic acids (PNAs) are often incorporated into therapeutic oligonucleotides to improve stability, binding affinity, and pharmacokinetic properties.

Manufacturing therapeutic oligonucleotides requires high purity and stringent quality control, supporting demand for specialized contract development and manufacturing organizations (CDMOs).

Technology Platforms

Synthetic oligonucleotide synthesis traditionally relies on phosphoramidite chemistry, which involves sequential addition of nucleotides to a growing DNA or RNA chain. Automated synthesizers enable production of large numbers of oligonucleotide sequences with high precision.

Purification techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry are used to ensure sequence accuracy and remove synthesis byproducts.

Emerging enzymatic DNA synthesis technologies are being developed as alternatives to traditional chemical synthesis methods. Enzymatic approaches may offer advantages in synthesis speed, environmental sustainability, and production of longer DNA sequences.

Automation and high-throughput synthesis platforms are improving efficiency and reducing turnaround time for custom oligonucleotide orders.

Integration of synthesis technologies with bioinformatics tools enables rapid design and ordering of custom sequences.

Market Drivers

Several factors are contributing to growth of the synthetic oligonucleotide synthesis market.

Expansion of genomics research and next-generation sequencing applications is increasing demand for custom DNA sequences.

Growth in nucleic-acid-based therapeutics is creating demand for high-quality RNA and DNA synthesis.

Increasing use of PCR-based molecular diagnostics is supporting recurring demand for primers and probes.

Advances in gene editing technologies are increasing demand for guide RNA synthesis.

Synthetic biology research is expanding use of engineered DNA constructs.

Increasing investment in personalized medicine is supporting development of targeted therapeutic approaches.

Automation of synthesis workflows is improving scalability and reducing cost per base.

Market Segmentation

The synthetic oligonucleotide synthesis market can be segmented by product type, application, end user, and geographic region.

By product type, DNA oligonucleotides represent the largest segment, followed by RNA oligonucleotides and modified oligonucleotides used in therapeutic applications.

By application, research applications represent a significant portion of demand, including PCR, sequencing, and gene editing workflows. Therapeutic applications represent a rapidly growing segment.

End users include academic research institutions, biotechnology companies, pharmaceutical companies, contract research organizations, and diagnostic laboratories.

North America represents the largest regional market due to strong biotechnology research infrastructure and pharmaceutical industry presence. Europe and Asia-Pacific markets are also expanding as investment in genomics research increases.

Competitive Landscape

The synthetic oligonucleotide synthesis market includes large life sciences companies, specialized synthesis providers, and contract manufacturing organizations.

Competition is driven by synthesis accuracy, turnaround time, cost efficiency, and ability to support complex modifications.

Companies are increasingly offering integrated solutions combining sequence design tools, synthesis services, purification, and analytical validation.

Strategic partnerships between synthesis providers and pharmaceutical companies are common, particularly in development of RNA-based therapeutics.

Intellectual property related to synthesis chemistry and nucleotide modifications plays an important role in competitive positioning.

Future Outlook

The synthetic oligonucleotide synthesis market is expected to continue expanding as genomic technologies and nucleic-acid-based therapeutics advance.

Enzymatic synthesis technologies may improve production efficiency and reduce environmental impact.

Advances in gene editing and synthetic biology may increase demand for longer and more complex DNA constructs.

Automation of synthesis workflows may reduce cost per base and increase scalability.

Integration of artificial intelligence tools into sequence design may improve performance of synthetic nucleic acids.

Expansion of RNA therapeutics pipelines is expected to drive demand for high-quality oligonucleotide manufacturing.

Overall, synthetic oligonucleotide synthesis represents a critical enabling technology for genomics research, molecular diagnostics, and precision medicine. Continued technological innovation and expanding therapeutic applications are expected to support sustained market growth.

Product Code: GENSYN 426

1 Market Guides

1.1 Situation Analysis
- 1.1.1 Strategic Role in Modern Biotechnology
- 1.1.2 Manufacturing Complexity and Scale-Up Challenges
- 1.1.3 Supply Chain Constraints and Capacity Expansion
- 1.1.4 Regulatory Complexity for Therapeutic Applications
- 1.1.5 Pricing Pressure and Cost Structure Challenges
- 1.1.6 Technology Innovation and Competitive Differentiation
- 1.1.7 Dependence on Genomics and Therapeutics Markets
- 1.1.8 Intellectual Property and Competitive Landscape
- 1.1.9 Geographic Market Dynamics
- 1.1.10 Outlook and Strategic Implications
1.2 Guide for Executives and Marketing Staff
1.3 Guide for Investment Analysts and Management Consultants
1.4 Impact of Artificial Intelligence

2 Introduction and Market Definition

2.1 What is Oligonucleotide Synthesis?
- 2.1.1 The Enzyme Race
- 2.1.2 Data Storage - The Elephant in the Room
2.2 Market Definition
- 2.2.1 Market Size
- 2.2.2 Currency
- 2.2.3 Years
2.3 Methodology
- 2.3.1 Methodology
- 2.3.2 Sources
- 2.3.3 Authors
2.4 Perspective: Healthcare and the IVD Industry
- 2.4.1 Global Healthcare Spending
- 2.4.2 Spending on Diagnostics
- 2.4.3 Important Role of Insurance for Diagnostics

3 Oligonucleotide Synthesis

3.1 Synthesis Technology
3.2 Automation
3.3 Types of Oligonucleotides
3.4 PCR Primers
3.5 PCR Assays and Panels
3.6 Sequencing
3.7 DNA Microarrays
3.8 Fluorescence In Situ Hybridization (FISH)
3.9 Antisense Oligonucleotides
3.10 Other Uses of Oligonucleotides
3.11 Relationship to CRISPR and Gene Editing

4 Industry Overview

4.1 Players in a Dynamic Market
- 4.1.1 Academic Research Lab
- 4.1.2 Diagnostic Test Developer
- 4.1.3 Instrumentation Supplier
- 4.1.4 Chemical/Reagent Supplier
- 4.1.5 Pathology Supplier
- 4.1.6 Independent Clinical Laboratory
- 4.1.7 Public National/regional Laboratory
- 4.1.8 Hospital Laboratory
- 4.1.9 Physicians Office Lab (POLS)
- 4.1.10 Audit Body
- 4.1.11 Certification Body

5 Market Factors

5.1 Factors Driving Growth
- 5.1.1 The Role of Diagnostics and the Covid Effect
- 5.1.2 The RNA Based Vaccine
- 5.1.3 Genomic Blizzard
- 5.1.4 Antisense Revival
- 5.1.5 New Applications
5.2 Factors Limiting Growth
- 5.2.1 Declining Price
- 5.2.2 Technology Lag
- 5.2.3 COVID Realignment
5.3 The Next Five Years

6 Oligonucleotide Synthesis Recent Developments

6.1 Recent Developments - Importance and How to Use This Section
- 6.1.1 Importance of These Developments
- 6.1.2 How to Use This Section
6.2 Ono Pharmaceutical to acquire antisense oligonucleotide treatment
6.3 Codexis Enables Manufacturing of RNAi Therapeutics
6.4 Codexis Successfully Uses Enzymatic Synthesis
6.5 Oligo Factory Achieves GMP Compliance
6.6 Oligonucleotide Synthesis Scaled Up
6.7 Antisense Oligonucleotide Lowers Tau Tangles
6.8 Ansa Biotechnologies Synthesizes Longest Oligo at 1005 Bases
6.9 Agilent will double oligonucleotide capacity
6.10 RNA Synthesis Technology Commercialized by EnPlusOne
6.11 Quick and Automated Printing of Custom Oligos
6.12 WuXi STA Opens Large-Scale Oligo Manufacturing Facility
6.13 Secarna Pharmaceuticals' and Evotec Achieve Programme Designation
6.14 Aligos Discontinues Development of its Antisense Oligonucleotide
6.15 Seegene Obtains CE Mark for Oligo Based SARS-CoV-2 Assay
6.16 Biofidelity to Launch Mutation Detection Assay
6.17 Oligonucleotide Therapeutics Society Holds Meeting
6.18 New Oligonucleotide Synthesis Chemistry
6.19 Antisense Oligonucleotides Cross Rodents' Blood-Brain Barrier
6.20 New Rapid Multiplexed PCR Assay Uses Oligo Probes
6.21 MIT Devises Oligo 'File System' for DNA Data Storage
6.22 Nuclera Acquires E Ink Digital Microfluidics Business
6.23 Twist Bioscience Hits Milestone for DNA Data Storage
6.24 Twist Bioscience, Vivlion Partner on RNA Libraries for CRISPR
6.25 DNA Script Launching Benchtop Synthesizer for 'DNA on Demand'
6.26 RNA Disease Dx to Develop PoC Covid Test
6.27 Evonetix and Analog Devices Develop GEN3 DNA Synthesis Platform
6.28 ATDBio Receives Grant for Cancer Diagnosis Project
6.29 Twist Bioscience Announces Therapeutic Ab
6.30 Drugmakers boost oligo capacity amid Covid-19
6.31 Aligos Therapeutics in Study of Oligo Candidate
6.32 DNA Script Raises $89M for SYNTAX Launch
6.33 Codexis & Molecular Assemblies Partner for DNA Synthesis
6.34 NuProbe Licenses Oligo Technology from Rice
6.35 Genome editing with Cas9-oligo conjugates
6.36 OliX Pharma and AM Chemicals Partner for RNA Synthesis Support
6.37 Twist Bio To End Trade Secrets Suit
6.38 DNA Script, partners get grant for data storage
6.39 Xi's STA unit opens oligonucleotide plant

7 Profiles of Key Companies

7.1 Abbott Laboratories
7.2 Agilent
7.3 Ajinomoto Bio-Pharma
7.4 Amyris
7.5 Ansa BioTechnologies
7.6 ATG:biosynthetics
7.7 ATUM
7.8 Azenta
7.9 Bayer
7.10 Beckman Coulter Diagnostics (Danaher)
7.11 Becton, Dickinson and Company
7.12 Biogen
7.13 Biolytic Lab Performance
7.14 Biomatik
7.15 bioMerieux Diagnostics
7.16 Bioneer Corporation
7.17 Bio-Rad Laboratories, Inc.
7.18 Biospring
7.19 Bio-Synthesis
7.20 Biotage
7.21 Blue Heron Biotechnology (Eurofins Genomic)
7.22 Camena Bioscience
7.23 Cepheid (Danaher)
7.24 Chemgenes
7.25 Codexis
7.26 Cytena
7.27 Diasorin S.p.A.
7.28 DNA Script
7.29 Enzo Biochem
7.30 Eurofins Scientific
7.31 Eurogentec (Kaneka)
7.32 Evonetix
7.33 FASMAC
7.34 GE Healthcare
7.35 Genomatica
7.36 Genscript Biotech
7.37 Glycogene Inc.
7.38 Hologic
7.39 Hongene Biotech
7.40 Innovassynth
7.41 Integrated DNA Technologies (Danaher)
7.42 Ionis Pharmaceuticals
7.43 J&J Innovative Medicine
7.44 Kern Systems
7.45 LGC Biosearch Technologies
7.46 Macrogen
7.47 Maravai LifeSciences Holdings
7.48 Merck & Co., Inc
7.49 Microsynth
7.50 Millipore Sigma
7.51 Molecular Assemblies
7.52 New England Biolabs, Inc.
7.53 Nippon Shinyaku
7.54 Nitto Denko (Avecia)
7.55 Nuclera
7.56 Oligo Factory
7.57 Panagene
7.58 Primerdesign (Novacyt)
7.59 Qiagen
7.60 Revvity
7.61 Roche Diagnostics
7.62 Seegene
7.63 Siemens Healthineers
7.64 Synthego
7.65 TAG Copenhagen A/S
7.66 Thermo Fisher Scientific
7.67 Twist Bioscience

8 Oligonucleotide Synthesis Global Market Overview

8.1 Global Market Overview by Country
- 8.1.1 Table - Global Market by Country
- 8.1.2 Chart - Global Market by Country
8.2 Global Market Size by Length - Overview
- 8.2.1 Table - Global Market by Length
- 8.2.2 Chart - Global Market by Length - Base/Final Year Comparison
- 8.2.3 Chart - Global Market by Length - Base Year
- 8.2.4 Chart - Global Market by Length - Final Year
- 8.2.5 Chart - Global Market by Length - Share by Year
- 8.2.6 Chart - Global Market by Length - Segment Growth
8.3 Global Market Size by Application - Overview
- 8.3.1 Table - Global Market by Application
- 8.3.2 Chart - Global Market by Application - Base/Final Year Comparison
- 8.3.3 Chart - Global Market by Application - Base Year
- 8.3.4 Chart - Global Market by Application - Final Year
- 8.3.5 Chart - Global Market by Application - Share by Year
- 8.3.6 Chart - Global Market by Application - Segment Growth
8.4 Global Market Size by Product - Overview
- 8.4.1 Table - Global Market by Product
- 8.4.2 Chart - Global Market by Product - Base/Final Year Comparison
- 8.4.3 Chart - Global Market by Product - Base Year
- 8.4.4 Chart - Global Market by Product - Final Year
- 8.4.5 Chart - Global Market by Product - Share by Year
- 8.4.6 Chart - Global Market by Product - Segment Growth
8.5 Global Market Size by Category - Overview
- 8.5.1 Table - Global Market by Category
- 8.5.2 Chart - Global Market by Category - Base/Final Year Comparison
- 8.5.3 Chart - Global Market by Category - Base Year
- 8.5.4 Chart - Global Market by Category - Final Year
- 8.5.5 Chart - Global Market by Category - Share by Year
- 8.5.6 Chart - Global Market by Category - Segment Growth
8.6 Global Market Size by Type - Overview
- 8.6.1 Table - Global Market by Type
- 8.6.2 Chart - Global Market by Type - Base/Final Year Comparison
- 8.6.3 Chart - Global Market by Type - Base Year
- 8.6.4 Chart - Global Market by Type - Final Year
- 8.6.5 Chart - Global Market by Type - Share by Year
- 8.6.6 Chart - Global Market by Type - Segment Growth

9 Global Market by Length

9.1 Less than 20 mer Market
- 9.1.1 Table - Less than 20 mer Market by Country
- 9.1.2 Chart - Less than 20 mer Market Segment Growth
9.2 21-50 mer Market
- 9.2.1 Table - 21-50 mer Market by Country
- 9.2.2 Chart - 21-50 mer Market Segment Growth
9.3 51-100 mer Market
- 9.3.1 Table - 51-100 mer Market by Country
- 9.3.2 Chart - 51-100 mer Market Segment Growth
9.4 Greater than 100 mer Market
- 9.4.1 Table - Greater than 100 mer Market by Country
- 9.4.2 Chart - Greater than 100 mer Market Segment Growth

10 Global Market by Application

10.1 Research Market
- 10.1.1 Table - Research Market by Country
- 10.1.2 Chart - Research Market Segment Growth
10.2 Diagnostics Market
- 10.2.1 Table - Diagnostics Market by Country
- 10.2.2 Chart - Diagnostics Market Segment Growth
10.3 Therapeutics Market
- 10.3.1 Table - Therapeutics Market by Country
- 10.3.2 Chart - Therapeutics Market Segment Growth
10.4 Data Market
- 10.4.1 Table - Data Market by Country
- 10.4.2 Chart - Data Market Segment Growth

11 Global Market by Product

11.1 Oligonucleotides Market
- 11.1.1 Table - Oligonucleotides Market by Country
- 11.1.2 Chart - Oligonucleotides Market Segment Growth
11.2 Instruments Market
- 11.2.1 Table - Instruments Market by Country
- 11.2.2 Chart - Instruments Market Segment Growth
11.3 Nucleosides Market
- 11.3.1 Table - Nucleosides Market by Country
- 11.3.2 Chart - Nucleosides Market Segment Growth
11.4 Other Reagents Market
- 11.4.1 Table - Other Reagents Market by Country
- 11.4.2 Chart - Other Reagents Market Segment Growth

12 Global Market by Category

12.1 Primer Market
- 12.1.1 Table - Primer Market by Country
- 12.1.2 Chart - Primer Market Segment Growth
12.2 Probe Market
- 12.2.1 Table - Probe Market by Country
- 12.2.2 Chart - Probe Market Segment Growth
12.3 DNA Market
- 12.3.1 Table - DNA Market by Country
- 12.3.2 Chart - DNA Market Segment Growth
12.4 RNA Market
- 12.4.1 Table - RNA Market by Country
- 12.4.2 Chart - RNA Market Segment Growth
12.5 Other Nucleic Acid Market
- 12.5.1 Table - Other Nucleic Acid Market by Country
- 12.5.2 Chart - Other Nucleic Acid Market Segment Growth

13 Global Market by Type

13.1 Standard Oligonucleotides Market
- 13.1.1 Table - Standard Oligonucleotides Market by Country
- 13.1.2 Chart - Standard Oligonucleotides Market Segment Growth
13.2 Custom Oligonucleotides Market
- 13.2.1 Table - Custom Oligonucleotides Market by Country
- 13.2.2 Chart - Custom Oligonucleotides Market Segment Growth

14 Appendices

14.1 Typical Oligo Synthesis Price Lists
14.2 Medicare Clinical Lab Fee Schedule
14.3 Drug Approvals by Molecule Type - A Seven Year View
14.4 Growth of Approved IVD Test Menu
14.5 Growth of Approved Average IVD Test Fee
14.6 Share of Pharma R&D by Country

Table of Tables

Table 1 Companies Formed to Exploit Enzyme Synthesis
Table 2 Market Players by Type
Table 3 Five Factors Driving Growth
Table 4 Three Factors Limiting Growth
Table 5 Global Market by Country/Region
Table 6 Global Market by Length
Table 7 Global Market by Application
Table 8 Global Market by Product
Table 9 Global Market by Category
Table 10 Global Market by Type
Table 11 Less than20 mer Market by Country
Table 12 21-50 mer Market by Country
Table 13 51-100 mer Market by Country
Table 14 Greater than 100 mer Market by Country
Table 15 Research Market by Country
Table 16 Diagnostics Market by Country
Table 17 Therapeutics Market by Country
Table 18 Data Market by Country
Table 19 Oligonucleotides Market by Country
Table 20 Instruments Market by Country
Table 21 Nucleosides Market by Country
Table 22 Other Reagents Market by Country
Table 23 Primer Market by Country
Table 24 Probe Market by Country
Table 25 DNA Market by Country
Table 26 RNA Market by Country
Table 27 Other Nucleic Acid Market by Country
Table 28 Standard Oligonucleotides Market by Country
Table 29 Custom Oligonucleotides Market by Country
Table 30 Clinical Lab Fee Schedule

Table of Figures

Figure 1 Global Health Spending
Figure 2 The Lab Test Pie
Figure 3 Phosphoramidites Structure
Figure 4 DNA/Oligonucleotide Synthetic Cycle
Figure 5 The Road to Diagnostics
Figure 6 Growth rates of Oligionucleotide Synthesis by Application
Figure 7 Market Size by Country
Figure 8 Global Market by Length - Base vs. Final Year
Figure 9 Length Market Base Year
Figure 10 Length Market Final Year
Figure 11 Length Share by Year
Figure 12 Length Segment Growth
Figure 13 Global Market by Application - Base vs. Final Year
Figure 14 Application Market Base Year
Figure 15 Application Market Final Year
Figure 16 Application Share by Year
Figure 17 Application Segment Growth
Figure 18 Global Market by Product - Base vs. Final Year
Figure 19 Product Market Base Year
Figure 20 Product Market Final Year
Figure 21 Product Share by Year
Figure 22 Product Segment Growth
Figure 23 Global Market by Category - Base vs. Final Year
Figure 24 Category Market Base Year
Figure 25 Category Market Final Year
Figure 26 Category Share by Year
Figure 27 Category Segment Growth
Figure 28 Global Market by Type - Base vs. Final Year
Figure 29 Type Market Base Year
Figure 30 Type Market Final Year
Figure 31 Type Share by Year
Figure 32 Type Segment Growth
Figure 33 Chart - Less than20 mer Market Growth
Figure 34 Chart 21-50 mer Market Growth
Figure 35 Chart - 51-100 mer Market Growth
Figure 36 Chart - Greater than 100 mer Market Growth
Figure 37 Chart Research Market Growth
Figure 38 Chart - Diagnostics Market Growth
Figure 39 Chart - Therapeutics market Growth
Figure 40 Chart - Data Market Growth
Figure 41 Chart Oligonucleotides Market Growth
Figure 42 Chart - Instruments Market Growth
Figure 43 Chart - Nucleosides Market Growth
Figure 44 Chart - Other Reagents Market Growth
Figure 45 Chart Primer Market Growth
Figure 46 Chart - Probe Market Growth
Figure 47 Chart - DNA Market Growth
Figure 48 Chart - RNA Market Growth
Figure 49 Chart - Other Nucleic Acid Market Growth
Figure 50 Chart Standard Oligonucleotides Market Growth
Figure 51 Chart - Custom Oligonucleotides Market Growth
Figure 52 Eurofins Price List
Figure 53 Hokkaido System Science Co. Price List
Figure 54 Biobasic Price List
Figure 55 Seven Years of FDA Approvals
Figure 56 IVD Test Menu Growth
Figure 57 IVD Test Average Fees - A Ten Year View
Figure 58 Share of Pharma R&D by Country